In patients with certain hematologic malignancies such as ALL and CLL, the use of autologous T cells genetically modified to express chimeric antigen receptors (CARs), such as the CD-19, has led to unprecedented clinical responses opening the door to a new era of personalized cancer therapy. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.